Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 19/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 0.65 |
| ▸ | CHUK | O15111 | 1/20 | 0.65 |
| ▸ | AKT1 | P31749 | 1/20 | 0.65 |
| ▸ | AKT2 | P31751 | 1/20 | 0.65 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19857799 | 1.00 | PADI4 (1.00) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19857755 | 0.95 | PADI4 (0.91) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19857754 | 0.95 | PADI4 (0.91) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19863768 | 0.92 | PADI4 (0.84) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19863739 | 0.92 | PADI4 (0.84) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19863770 | 0.91 | PADI4 (0.84) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19857874 | 0.91 | PADI4 (0.87) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19857873 | 0.91 | PADI4 (0.87) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19857765 | 0.90 | PADI4 (1.00) | PADI4IKBKBCHUKAKT1AKT2 | |
| SCHEMBL19857766 | 0.90 | PADI4 (1.00) | PADI4IKBKBCHUKAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| EP-4073054-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | Fondazione Istituto Italiano di Tecnologia (IT) | 2022-10-19 | — | — | EP | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | RAD51, BRCA1, FANCI | PADI4 4745/4885IKBKB 1476/4885CHUK 1593/4885 |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | EIF4E, EIF4A1, EIF4A2 | PADI4 4191/4885IKBKB 1115/4885CHUK 724/4885 |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | PADI4 1/4885IKBKB 1218/4885CHUK 923/4885 |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | EIF4E, EIF4A1, EIF4A2 | PADI4 4191/4885IKBKB 1115/4885CHUK 724/4885 |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | PADI4 1/4885IKBKB 1218/4885CHUK 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.